S-3304

DCTPepD ID  DCTPepD0045

Active Ingredients   S-3304

Description  An orally-agent agent with potential antineoplastic activity. S-3304 inhibits matrix metalloproteinases (MMPs), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.

Synonyms  MMP Inhibitor S-3304; S-3304

Disease  Lung Cancer, Solid Tumors, Non Small Cell Lung Cancer

Classification

  

MMP inhibitor Amino acid and derivative

Structure Information


Molecular Formula  C24H20N2O4S2

Molecular Weight  464.6

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (2R)-3-(1H-indol-3-yl)-2-[[5-[2-(4-methylphenyl)ethynyl]thiophen-2-yl]sulfonylamino]propanoic acid

InChI  InChI=1S/C24H20N2O4S2/c1-16-6-8-17(9-7-16)10-11-19-12-13-23(31-19)32(29,30)26-22(24(27)28)14-18-15-25-21-5-3-2-4-20(18)21/h2-9,12-13,15,22,25-26H,14H2,1H3,(H,27,28)/t22-/m1/s1

InChI_Key YWCLDDLVLSQGSZ-JOCHJYFZSA-N

SMILES  CC(C=C1)=CC=C1C#CC2=CC=C(S2)S(=O)(N[C@@H](C(O)=O)CC3=CNC4=C3C=CC=C4)=O

External Codes


PubChem CID  10718956

DrugBank Accession Number  DB12149

NCI Thesaurus Code  C2671  

UNII  BK459F050X   GSRS

CAS  203640-27-1



Drug approval


Drug indication
    S-3304 has been used in trials studying the treatment of Lung Cancer, Solid Tumors, Non Small Cell Lung Cancer, Stage IIIB Non Small Cell Lung Cancer, and Stage IIIA Non Small Cell Lung Cancer, among others.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT00078390 A Phase I/II Study of the Safety, Pharmacokinetic Interaction and Efficacy of S-3304 in Combination With Standard Therapy in Patients With Locally Advanced Non-small Cell Lung Cancer. Non Small Cell Lung Cancer; Lung Cancer; Stage IIIA Non Small Cell Lung Cancer; Stage IIIB Non Small Cell Lung Cancer Phase 1/2 Treatment
NCT00033566 A Phase I Study of S-3304 in Patients With Solid Tumors Unspecified Adult Solid Tumor, Protocol Specific Phase 1 Treatment
NCT00033215 A Phase 1 Study of S-3304 in Patients With Solid Tumors Solid Tumors Phase 1 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DCTPep is developed by Dr.Zheng's team.